Welcome to our dedicated page for CORE ONE LABS news (Ticker: CLABF), a resource for investors and traders seeking the latest updates and insights on CORE ONE LABS stock.
Core One Labs Inc. (CLABF) is a pioneering life sciences biotechnology research and development company focusing on psychedelic medicines. The company, through its subsidiaries, is dedicated to bringing psychedelic compounds to market, advancing psychedelic-assisted treatments, and integrating novel delivery systems technology. With a multifaceted business approach, Core One holds a key interest in developing proprietary psilocybin production systems and formulations targeting neurological and mental health disorders. Their recent achievements include conducting animal model studies to evaluate bio-compounds' effectiveness in treating diseases like Alzheimer's, Parkinson's, Stroke, and Depression, showing promising results that could revolutionize the treatment landscape.
Core One Labs Inc. (OTCQB:CLABF) has initiated a commercial sales strategy for its proprietary biosynthetic psilocybin product. This strategy aims to establish long-term revenues by attracting and retaining new customers while forging key partnerships, particularly with pharmaceutical companies and clinics. With increasing global demand for psychedelic therapies, Core One positions itself as a leading supplier of pharmaceutical-grade psilocybin. The company holds multiple provisional patents related to psychedelics and has access to a database of over 275,000 patients through its medical clinics.
Core One Labs Inc. has engaged in discussions with a contract development and manufacturing organization (CDMO) for the GMP-compliant production of its biosynthetic psilocybin product. The collaboration aims to achieve commercial-scale production, potentially revolutionizing the psychedelics market by providing a safe, reliable, and cost-efficient source of psilocybin. The proprietary production system is anticipated to significantly reduce costs from current market prices, which range from US$3,000 to US$10,000 per gram. This agreement could expand the company's client base and drive revenue growth.
Core One Labs Inc. (OTCQB:CLABF) announced positive results from pharmacokinetics studies conducted by its subsidiary, Akome Biotech Ltd. The studies indicate promising performance of psychedelic-based bioactive compounds targeting mental health conditions such as Major Depressive Disorder, Stroke, Parkinson's Disease, and Alzheimer's Disease. These advancements mark a crucial milestone in Core One's pre-clinical development and support the drug discovery process towards potential regulatory approval.
Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF) has announced significant findings from neurogenesis studies conducted by its subsidiary, Akome Biotech Ltd. The research indicates that specific bioactive compounds have the potential to stimulate neurogenic activity, showcasing their effectiveness against various neurological conditions. The results may allow the company to broaden its patent applications, expanding beyond single compound-targeted diseases. Further testing will explore combinations of these compounds with psychedelics, with upcoming animal studies planned to validate therapeutic effects.
Core One Labs Inc. (OTCQB:CLABF) announced that its subsidiary Vocan Biotechnologies has successfully converted a psilocin precursor into psilocybin using enzymatic methods. This process yielded approximately 160 grams of contaminant-free psilocybin from 220 grams of psilocin precursor. The company anticipates increased production capabilities with new equipment and a GMP-compliant contract manufacturer. Core One aims to contribute to the growing field of psychedelic medicine for mental health treatment, emphasizing their commitment to enhancing shareholder value.
Core One Labs Inc. (OTCQB: CLABF) has announced its upgrade from the OTC Pink Market to the OTCQB Venture Market, effective April 6, 2022. This upgrade is expected to enhance liquidity and broaden access to both institutional and retail investors. The OTCQB is recognized by the SEC for providing public information that aids in securities analysis. Core One aims to leverage this increased visibility to advance its business in the burgeoning psychedelic market.
Core One Labs Inc. (CSE: COOL, OTC: CLABF) announced promising outcomes from its subsidiary Akome Biotech's collaboration with Neuro-Zone in developing psychedelic-based bioactive compounds for neurological conditions such as Alzheimer’s and Parkinson’s. The in vitro bioassay studies confirmed the efficacy of Akome's plant bioactives in targeting neuropathological mechanisms associated with these diseases. These findings mark a significant step towards groundbreaking drug formulations, positively impacting millions suffering from these conditions.
Core One Labs Inc. (OTC: CLABF) is exploring investment and acquisition opportunities with major pharmaceutical companies. CEO Joel Shacker emphasizes that as research on psychedelics for treating mental health issues progresses, the market for these drugs is expanding, prompting pharmaceutical consolidation. Core One is innovating in psychedelic medicine, holding multiple patents for psilocybin production and formulations targeting mental health disorders. Additionally, the company manages four medical clinics with over 275,000 patients to advance psychedelic-based treatments.
Core One Labs Inc. (OTC: CLABF) announced a collaboration between its subsidiary, Vocan Biotechnologies, and Awakened Biosciences to enhance psilocybin production methods. This partnership aims to leverage Awakened's innovative technologies to produce cost-effective synthetic psilocybin at scale. Notable figures like Dr. Tony Durst, a specialist in medicinal chemistry, will contribute to the effort. CEO Joel Shacker emphasized that this collaboration positions Core One as a leader in the industry and supports its growth strategy in psychedelic medicine.
Core One Labs Inc. (OTC: CLABF) announced progress in expanding the production of its proprietary biosynthesized psilocybin API through its subsidiary, Vocan Biotechnologies. This method provides a highly pure psilocybin source for pharmaceutical manufacturers and compounding pharmacies under Health Canada's Special Access Program. The technology allows precise dosing and complies with GMP standards, positioning Core One as a leader in the psychedelic space. CEO Joel Shacker emphasized the aim to partner with organizations seeking high-quality psilocybin for treatments and studies.
FAQ
What is the current stock price of CORE ONE LABS (CLABF)?
What is the market cap of CORE ONE LABS (CLABF)?
What is Core One Labs Inc. known for?
What are some recent achievements of Core One Labs Inc.?
What is the business approach of Core One Labs Inc.?
How does Core One Labs Inc. differentiate itself in the market?
What are the potential benefits of Core One Labs Inc.'s animal model studies?
